NRX Pharmaceuticals, Inc. (NASDAQ:NRXP)
| Market Cap | $96.12M-14.3% |
| Revenue (ttm) | $3.39M |
| Net Income | -$23.48M+30.5% |
| EPS | -$0.74+68.1% |
| Shares Out | 43.30M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,209.81 |
| Open | $2.25 |
| Previous Close | $2.28 |
| Day's Range | $2.21 - $2.26 |
| 52-Week Range | $1.62 - $5.06 |
| Beta | 2.07 |
| Analysts | Buy |
| Price Target | $2.00(-9.91%) |
| Earnings Date | Nov 16, 2026 |
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
3 firms rating NRXP in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Nov 16, 2026Earnings report
$NRXP stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in NRXP holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NRXP's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NRXP Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New NRXP patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NRXP from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NRXP
| VTIVanguard Morningstar Total Stock Market ETF | $3.70M |
| PSILAdvisorShares Psychedelics ETF | $1.69M |
| VXFVanguard Extended Market ETF | $1.42M |
| IWCiShares Micro-Cap ETF | $249.72K |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from NRXP’s recent data — informational, not investment advice
What’s Behind the Score
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| PSIL | AdvisorShares Psychedelics ETF | 3.96% |
Weight is the stock’s share of each fund’s holdings.